MDM2 and acute myeloid leukemia: MDM2 is a potential therapeutic target investigated in the MIRROS clinical trial (NTC02545283) by administering the MDM2 antagonist molecule Idasanutlin to patients with r/r AML concomitantly with Ara-C treatment.